Trade Cumberland - CPIX CFD

Trading Conditions

• Spread: 0.0784
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 1.5958
• Open: 1.5658
• 1-Year Change: -14.9%
• Day's Range: 1.5658 - 1.7558

Cumberland Company profile

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).

Equity composition

Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.